Five years after Harvard researchers first received institutional permission to attempt to produce stem cell lines via somatic cell nuclear transfer (SCNT), a young scientist who worked in the Harvard program as a postdoctoral fellow has succeeded in using the process — known as therapeutic cloning — to produce a stem cell line containing the genes of a patient with type 1 diabetes.
In papers in Nature, Nature Communications, and Cell Stem Cell, that scientist, who is now at the independent New York Stem Cell Foundation (NYSCF) laboratory, and Harvard researchers, report on the SCNT advance. In addition, they report on an experiment explaining why other attempts at
And now there are three: in the wake of announcements from laboratories in Oregon and California that they had created human embryos by cloning cells of living people, a lab in New York announced on Monday that it had done that and more.
In addition to cloning the cells of a woman with diabetes, producing embryos and stem cells that are her perfect genetic matches, scientists got the stem cells to differentiate into cells able to secrete insulin.
That raised hopes for realizing a long-held dream of stem cell research, namely, creating patient-specific replacement cells for people with diabetes, Parkinson’s disease,
Sir John Gurdon
One of the most prestigious prizes in medicine is being awarded this year to scientists working on stem cells and leukemia — and to New York‘s mayor for his fight to cut tobacco use (…)
The Lasker Basic Medical Research Award goes to John Gurdon, 76, of Cambridge University and Shinya Yamanaka, 47, of Kyoto University and San Francisco‘s Gladstone Institute of Cardiovascular Disease. Their work has helped pave the way for the possibility of made-to-order stem cell treatments for individual patients
Gurdon began working with frog eggs in the 1950s and was the first to successfully clone